The CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is Associated with Poorer Survival

• Janice A. Royds,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Shafagh Al Nadaf,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Anna K. Wiles,

  Affiliation Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Yu-Jen Chen,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Antonio Ahn,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Alisha Shaw,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Sara Bowie,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Frederic Lam,

  Affiliation Zenith Technology, Dunedin, New Zealand

  ⨯
• Bruce C. Baguley,

  Affiliation Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

  ⨯
• Antony W. Braithwaite,

  Affiliations Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, Children's Research Institute, University of Sydney, Westmead, Australia

  ⨯
• Martin R. MacFarlane,

  Affiliation Christchurch Hospital, Christchurch, New Zealand

  ⨯
• Noelyn A. Hung,

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯
• Tania L. Slatter

  * E-mail: tania.slatter@otago.ac.nz

  Affiliation Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

  ⨯